This trial is testing a new drug for people with primary generalized tonic-clonic seizures. The drug is taken once a day, either in the morning or evening. The treatment period is 22 weeks, with a 3 week follow up period.
1 Primary · 0 Secondary · Reporting Duration: 28 Days
Experimental Treatment
Non-Treatment Group
170 Total Participants · 2 Treatment Groups
Primary Treatment: Cenobamate · Has Placebo Group · Phase 3
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: